Weighing the GHK-Cu record, one citation at a time

What GHK-Cu Buy is

Think of GHK-Cu Buy as a reading desk kept on a single subject: the published science of GHK-Cu, the copper-binding tripeptide. Every page is a summary of that peer-reviewed record, written for a reader who wants the findings without the sales gloss. Nothing is diagnosed or prescribed here, no dose is recommended, and no reader is told what to do with their body — the desk reports studies, it does not counsel patients. Nor is there anything to buy: no dispensary, no order line, no supplier pointed toward.

The copper-peptide field earns this care because it is genuinely interesting and genuinely easy to overstate — thirty years of in vitro and rodent work, a handful of small human topical trials, and a great deal of secondary commentary that blurs the line between the two ^[3][6]. This desk reads the primary record and keeps that line visible.

What the name means

The noun in the domain — "Buy" — is a piece of editorial framing, not an offer. Reading it as a checkout would miss the point: there is no cart, no broker, no quiet referral to a source. What the word marks is a vantage point, the place a reader stands when the question is what the copper-tripeptide research actually supports rather than what it is merely rumored to. That, and nothing transactional, is what the name means.

We also draw a hard distinction the literature often blurs: Copper Tripeptide-1, the topical cosmetic ingredient, has a long safety record, while injectable or systemic GHK-Cu is an unapproved research chemical with no validated human pharmacokinetics ^[6]. Where this brief discusses systemic doses, it reports them as the parameters of a cited study in a named species — never as guidance for a person.

The editorial standard

There is one rule the desk answers to: every number on the site — each dose, percentage, n-value, molecular weight, and effect size — traces to a numbered source in a genuine peer-reviewed study, review, or plainly labeled preprint ^[1][2][4]. Preclinical data is called preclinical; a bioRxiv preprint is flagged as one; and where human pharmacokinetics are simply missing, the gap is marked rather than papered over ^[8][14].

A particular caution runs through the GHK-Cu field: a large share of the foundational mechanistic and review literature originates from a single investigator group, so the broadest gene-expression and anti-aging claims await independent replication ^[2][6]. We surface that limitation rather than launder it, and we revise as the record changes.

The measured register is a choice, not timidity. GHK-Cu's headline figures — a peptide touching roughly a third of the human transcriptome, sharpening cognition in aged mice — are precisely the sort that get rounded upward into marketing copy ^[2][8]. A memorandum is the right vessel for them: it can state each result at full strength and, in the same sentence, name the species, the route, and the missing human data. Holding that balance on every page is the standard this reading desk was built around.